Mounjaro®, heartburn and indigestion

Three terms for one kind of discomfort

Dyspepsia is the medical word for indigestion: discomfort, fullness or burning in the upper stomach. Gastroesophageal reflux disease, or GERD, means stomach contents flowing back into the food pipe, which is what most people mean by heartburn. Eructation is burping. Only dyspepsia reached the 5% threshold for the US label’s main table; the other two sit in the text below it, among reactions more frequent on Mounjaro® than on placebo ^[1].

Health Canada’s monograph prints all three for the same two placebo-controlled diabetes trials, unrounded, and for a larger pool of seven phase 3 trials with 5,119 people on tirzepatide and a mean exposure of 48.1 weeks ^[4].

What the dose pattern does and does not show

In the small placebo-controlled pool, dyspepsia is highest on the two lower doses and reflux peaks at 10 mg, so no clear dose rule appears ^[4]. In the larger seven-trial pool, reflux and burping edge upwards from 5 mg to 15 mg, while dyspepsia stays between about 6% and 7% ^[4]. These are group results from trials not designed to compare one symptom across doses, so they cannot tell you how a particular dose step will affect you.

The European information puts dyspepsia, reflux, burping, abdominal bloating and wind in its “common” band, meaning up to 1 person in 10 ^[3]. Neither the SURPASS-CVOT heart trial nor the pediatric trial singles out these reactions as different, and the US label’s sentence about reactions easing after the step-up names nausea, vomiting and diarrhea only ^[1]. A meta-analysis found dyspepsia more frequent with tirzepatide 15 mg than with insulin ^[6].

What a reporting study adds

A 2026 study looked at reflux reports in three national adverse event databases, from the United States, Japan and Canada, comparing GLP-1 medicines with DPP-4 inhibitors, another class of diabetes tablets. Reflux was reported more often for every GLP-1 medicine studied; for tirzepatide the reporting ratio ranged from 2.76 to 5.77 across the databases. The signal strengthened with age and was strongest in people 65 and older ^[5].

This type of study counts spontaneous reports. It shows that reflux is reported out of proportion with these medicines, which is a reason for attention, but it cannot show how often reflux happens or prove that the medicine caused a given case ^[5].

Why a slower stomach may lead to heartburn

What the label supports: tirzepatide delays stomach emptying, the delay is largest after the first dose, and it becomes smaller with later doses ^[1]. The label does not tie dyspepsia or reflux to this directly.

What is plausible but unmeasured for Mounjaro®: according to MedlinePlus, reflux occurs when the muscular valve where the food pipe meets the stomach fails to seal, and a full stomach pushes harder against that valve when you lie down ^[7][11]. A stomach that stays full for longer could make that more likely, especially after an evening meal. No tirzepatide study has tested this directly.

One more point from the labels: the same slowing can affect how tablets are absorbed, and food may remain in the stomach during anaesthesia or deep sedation, which is why the label asks you to tell every clinician before a planned procedure that you take Mounjaro® ^[1][2].

Other causes of heartburn

Heartburn is common with or without tirzepatide. MedlinePlus and the NIH list a hiatal hernia, pregnancy, smoking, overweight and a range of medicines among causes, including some blood pressure medicines (beta blockers and calcium channel blockers), certain asthma medicines, sedatives, tricyclic antidepressants, progestin used for bleeding or contraception and anti-inflammatory painkillers ^[7][8][11].

Food and drink matter too. Alcohol, caffeine, fizzy drinks, chocolate, citrus, tomatoes, mint and spicy or fatty food are common triggers ^[7][10]. If a new medicine or habit started at about the same time as your Mounjaro® dose step, mention both to your clinician, and do not stop a prescribed medicine without talking to them first ^[7].

What may help

None of the Mounjaro® documents gives reflux self-care advice. MedlinePlus and the NIH do; talk to your provider if heartburn persists despite these steps ^[7].

• Eat smaller meals, and avoid bending over or exercising straight after eating ^[7].
• Leave a few hours between your last meal and bedtime, and avoid snacking after dinner ^[7][11].
• If symptoms are worse at night, raise the head end of the bed, for example with blocks under the legs or a wedge ^[7][9].
• Notice which foods and drinks set you off, and cut back on them with your doctor’s input ^[10].
• Avoid tight belts and waistbands, and stop smoking if you smoke ^[7].
• Antacids, H2 blockers and proton pump inhibitors are available over the counter. The NIH advises against daily antacid use without a doctor’s input, and because tirzepatide can change how tablets are absorbed, ask your pharmacist before starting one ^[1][9].

Questions for your prescriber

Useful notes: how often heartburn comes, whether it is worse at night or after large or late meals, whether it follows your injection day or a dose step, and what you take for it. Mention any swallowing difficulty, weight loss you did not plan, or prolonged burping and bloating with nausea, which Canada’s patient information links to gastroparesis ^[4]. Your prescriber decides whether any change to your treatment is needed.

Mounjaro® is a registered trademark of Eli Lilly and Company. PepLabo is not affiliated with or endorsed by Eli Lilly and Company.

When to get help